VERAXA Partners with Ardigen on AI Cancer Discovery
ZURICH, Switzerland, July 13, 2026 VERAXA Biotech announced a strategic collaboration with AI-driven computational biology company Ardigen to accelerate...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
ZURICH, Switzerland, July 13, 2026 VERAXA Biotech announced a strategic collaboration with AI-driven computational biology company Ardigen to accelerate...
